Key Takeaways
- Strong top line despite erratic monsoon: Revenue grew ~25% YoY in Q2, driven by new product launches and a 6-7% price increase, even as unseasonal rains disrupted cropping patterns across India.
- Margins hit by twin external shocks: EBITDA growth was dented by expensive raw material purchases forced by global shortages and a ~₹13 cr currency depreciation hit, delaying the expected margin recovery.
- New product engine is firing: Shinwa is on track to become the #1 product next year, crossing ₹100 cr in sales, while the top three new products together are projected to cross ₹300 cr next fiscal.
- Capacity build-out nears completion: Dahej plant expansion (50%+ capacity increase) starts production in January, and a new Rajasthan site acquired via NCLT will be ready for the next Kharif season, securing growth for at least two years.
- What to watch next quarter: Whether the promised H2 margin recovery materializes as raw material prices soften, and if the export business stabilizes enough to hit the revised ₹250 cr target.
Top-Line Performance & Monsoon Impact
- Erratic monsoon disrupted cropping: Heavy, untimely rains in Central and South India, combined with dry conditions in the East and parts of the North, affected sowing of rice, pulses, oil seeds, and cotton, delaying harvests and causing yield losses.
- Growth came from new products: Despite the adverse weather, revenue increased 31% YoY, with price growth contributing 6-7% and the balance coming from volume, majorly from new launches and products launched in the prior year.
- H1 growth drivers: The insecticide and herbicide ranges were the major contributors to first-half growth.
- Obsolete product recovery complete: Management claims 100% recovery of the ~₹250 cr in sales lost when MONOCIL and AVONE were banned, achieved entirely through new product introductions.
Rajesh Aggarwal: "Q2 was little challenging because of the adverse monsoon pattern because we have observed that there were heavy, untimely and un-required rains in many areas and then some of the areas were very dry."
Margin Headwinds & Recovery Path
- Two external factors compressed margins: Global supply chain disturbances caused acute chemical shortages and container unavailability, forcing the company to buy raw materials at elevated prices without being able to pass costs on. Simultaneously, broad-based currency depreciation against the dollar delivered a ~₹13 cr negative impact on profitability.
- Inventory risk contained: Management sees no inventory write-down impact this quarter because the market is in a super off-season with very low global demand, and price correction in India has not yet started in a significant way.
- China raw material prices softening: In the last 20 days, prices of many raw materials have become very cheap, creating an opportunity to restart purchases at lower costs.
- Recovery timeline: Management expects EBITDA percentage to improve from H2 onwards, with good margin recovery visible from Q1 of the next fiscal itself, and a sustainable EBITDA margin profile greater than 15% in coming years.
Rajesh Aggarwal: "Number one is the international disturbance due to which the crop prices of the chemicals has changed a lot. There were acute shortages, there were shortages of containers due to which we were forced to buy some products at expensive prices actually and we could not get the same price from that market... the second impact was due to the currency because all the currencies across the world have depreciated in front of dollar which has given a very negative impact actually on the margins of the company."
New Product Pipeline & Strategy
- Product portfolio strategy: The company divides its range into Maharatna and Focus Maharatna products, which carry better margins and stronger growth prospects. These categories contributed 30% of brand sales each, with a 6% YoY increase in these products.
- Shinwa trajectory: Launched this year, Shinwa (insecticide) is expected to become the #1 product next year, crossing ₹100 cr in sales.
- Top three products: Shinwa, Hachiman (herbicide, launched last year), and Torry (herbicide, launched around March/April) together are projected to cross ₹300 cr in the next fiscal.
- New fungicides: Izuki (a mixture product extended from the Nissan portfolio) and Stunner (a fungicide manufactured for the first time in the country) launched in Q2 with good initial response; sales are expected to multiply next year.
- R&D pipeline: About one dozen products are coming out of R&D and from the Japanese partner in the next 6 to 8 months, including new-generation molecules, off-patented products, and patented technologies from Nissan, to be launched as registrations are received.
- Mix shift to solutions: The industry trend is moving from single generic products toward IP-protected mixtures, as consumers increasingly seek solutions rather than standalone products.
Rajesh Aggarwal: "Shinwa, Hachiman and Torry they will be our top three products actually in the new cycle and my vision will be to cross 100 crores with each produced individually, but I can say at least all these three products put together will be crossing 300 crores for sure in the next fiscal itself."
Capacity Expansion & Backward Integration
- Dahej plant expansion: About 30 reactors added, with production starting in the first week of November, increasing capacities by more than 50%. The plant is expected to be fully operational from January, bringing advantages from the next Kharif season onward through backward integration, new molecule manufacturing, and reverse engineering to reduce imports and save costs.
- Rajasthan site acquisition: An old factory is being purchased through NCLT, with the deal expected to close by December. The site will house a formulation unit, R&D centers, a technical plant, and biological activity, and will be available for the coming Kharif season.
- Backward integration focus: Investment is directed at manufacturing basic chemicals required for synthetic pyrethroids (lambda-cyhalothrin, bifenthrin, Dynathofram) to substitute imports and become a more reliable global supplier.
- Capacity runway secured: All extensions being completed now will support increasing market share for at least the next two years.
- Dahej infrastructure: A 1 MW solar power plant and a 9,000 square meter storage facility (not in initial plans) were also completed at the Dahej unit.
Biologicals & New Subsidiary
- IIL Biological Limited: A new wholly owned subsidiary has been set up to house the biologicals business, which the company entered 5-6 years ago and has maintained through an R&D center and lease manufacturing.
- Dedicated facility: A new site midway on the Delhi-Jaipur highway has been finalized for the IIL Biological plant, alongside consolidation of IIL formulations and a separate R&D center for biologicals. The biological investment within the ~₹150 cr Rajasthan project is estimated at not more than ₹20 cr, using a pre-constructed building requiring mainly renovation plus plant and machinery.
- Market context: The biologicals market is still nascent at less than 5% of the global agrochemical market, but companies are now focusing on it due to international pressures, and management expects it to gain good market size.
- GLP certification: IIL received Good Laboratory Practice certification from the Government of India, making it the 52nd company across all sectors to receive this accreditation, which makes its data acceptable worldwide.
Exports & International Markets
- Mixed international demand: Demand is good in many parts of Africa, but currency deterioration is very high and dollar shortages in many countries are causing orders to be stuck.
- Export target maintained: The initial export target of ₹200 cr has been revised upward to ₹250 cr, and management is working toward this target despite challenges, viewing this year as a stabilization period before growing exports in a big way next year.
- European registration breakthrough: IIL has started exporting lambda-cyhalothrin to various European countries backed by one European registration valid in 17 countries, with both small and large orders beginning to flow.
- International registrations push: The company is working on registering products in international markets in a big way, expecting registrations to click in advanced markets of America and Europe.
- Export margin profile: Generic export sales operate on high single-digit to 10% maximum margins; exporting new-generation molecules or signing CRAMS agreements with large companies can yield additional margins with lower marketing expenses.
Rajesh Aggarwal: "We had initially kept the target of 200 crore means 200 crores of export sales, which I have revised 250 crores. I believe that I will still keep that target in mind and we will be working our international team will be working for this target..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Top-line growth | Very strong double-digit growth in top line this fiscal; 20%+ growth in H2 FY23 | FY23 |
| EBITDA margin recovery | EBITDA percentage to improve from H2; good recovery from Q1 of next fiscal; sustainable margin profile greater than 15% | H2 FY23 onward; Q1 FY24 |
| Shinwa sales | Cross ₹100 cr sales, become #1 product | Next fiscal (FY24) |
| Top three new products | Shinwa, Hachiman, Torry together cross ₹300 cr | Next fiscal (FY24) |
| Dahej plant | Fully operational, backward integration benefits begin | January 2023; next Kharif season |
| Rajasthan site | Available for formulation in Kharif season | Kharif season (2023) |
| Export sales | Achieve revised target of ₹250 cr | FY23 |
| Working capital | Reduce total stocks in a big way by increasing sales and reducing purchases | Q3 FY23 |
| New product launches | About one dozen products from R&D and Japanese partner | Next 6 to 8 months |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue from operations | ₹582 cr, up ~31% YoY from ₹444 cr |
| EBITDA | ₹69 cr, up ~6.68% YoY from ₹64 cr |
| PAT | ₹45 cr, up ~6.35% YoY from ₹42 cr |
| Price growth | ~6% to 7%, balance is volume growth |
| Currency impact on profitability | ~₹13 cr hit |
| H1 FY23 total revenue growth | ~25% increase |
| H2 FY23 revenue growth guidance | 20% plus growth expected |
| Export sales target | ₹250 cr, revised from initial ₹200 cr |
| Dahej project cost escalation | ~30% from pre-COVID estimates |
| Chopanki capacity increase | More than 50% plus |
| Focus Maharatna sales contribution | 30% of sales |
| Maharatna brand sales contribution | 30% of brand sales |
| Chhattisgarh fraud outstanding | ~₹10 cr plus still in the market |
| Rajasthan new project total budget | ~₹150 cr |